Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q4 2020 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Lyra Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Lyra Therapeutics (LYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Lyra Therapeutics (LYRA)

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer

Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lyra Therapeutics, Inc. ("Lyra" or "the Company") (NASDAQ: LYRA) for violations of the securities laws. The...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021

Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021

LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of CRS

Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps

Lyra is to report top line data of its Phase 2 Trial in December. All indications are the trial should be a success, and they have strong backing from Perceptive Advisors.

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference

Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors

Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors

Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance

Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis

Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic Society Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic Society

Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2020 Results - Earnings Call Transcript

WATERTOWN, Mass., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 12:30 p.m. ET.

Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference

WATERTOWN, Mass., July  30, 2020  (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, August 6, 2020 at 10:00 a.m. ET.

Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference

WATERTOWN, Mass., July  24, 2020  (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced the company will release second quarter 2020 financial results on Wednesday, August 5, 2020 after the close of market. Lyra will host a corresponding conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Lyra Therapeutics: Advancing An Innovative Solution For Chronic Rhinosinusitis

WATERTOWN, Mass., July  07, 2020  (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced the appointment of Robert Richard, Ph.D., to the position of Senior Vice President of Research and Development. He is a research and development (R&D) veteran who possesses extensive leadership and product development experience in drug delivery and complex combination products. Dr. Richard will oversee development for Lyra’s two product candidates for the treatment of chronic rhinosinusitis, and lead efforts on platform expansion, including next generation technologies that support new indications.

Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development

Lyra Therapeutics completed its IPO in late-April selling 3.5m shares at a price of $16 - the higher end of expectations - to raise $56m.

Lyra Therapeutics: A Chance To Pick Up This ENT Play As It Plateaus Post-IPO

WATERTOWN, Mass., May  28, 2020  (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today reported financial results for the quarter ended March 31, 2020 and provided a corporate update.

Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Shares of Lyra Therapeutics Inc., a biotech specializing in treatments for ear, nose and throat diseases, soared 32% in their trading debut Friday, after the company's initial public offering priced at the top end of the range.

News for Lyra Therapeutics Stock (LYRA)